CLRB - セレクタ・バイオサイエンシ―ズ (Cellectar Biosciences Inc.) セレクタ・バイオサイエンシ―ズ

 CLRBのチャート


 CLRBの企業情報

symbol CLRB
会社名 Cellectar Biosciences Inc (セレクタ・バイオサイエンシ―ズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Cellectar Biosciences Inc. formerly Novelos Therapeutics Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic PDC''s. The Company''s PDC product portfolio includes CLR 131 which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125 which is for the treatment of micro metastatic disease; CLR 124 which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502 which is for intraoperative tumor margin illumination and non-invasive tumor imaging and CTX Product Portfolio including CLR 1601-PTX CLR 1602-PTX and CLR 1603-PTX product candidates.   セレクタ・バイオサイエンシ―ズは米国のバイオ医薬品企業。癌治療薬、癌標的の投影剤の開発に従事。同社の癌注力技術は癌幹細胞を含む癌細胞に対する薬剤の選択的送達を可能にする。開発中の製品候補は、癌標的陽電子放射断層撮影造影剤I-124-CLR1404、癌標的分子放射線治療I-131-CLR1404、非放射光造影剤CLR1502など。   Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June 1996 and is headquartered in Florham Park, NJ.
本社所在地 3301 Agriculture Drive Madison WI 53716 USA
代表者氏名 Stephen Anthony Hill スティーブン・アンソニー・ヒル
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 608-441-8120
設立年月日 35217
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数
url www.cellectar.com
nasdaq_url https://www.nasdaq.com/symbol/clrb
adr_tso
EBITDA EBITDA(百万ドル) -12.53883
終値(lastsale) 2.715
時価総額(marketcap) 10311094.875
時価総額 時価総額(百万ドル) 10.21615
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 6.03918
当期純利益 当期純利益(百万ドル) -15.39489
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectar Biosciences Inc revenues was not reported. Net loss increased 6% to $6.4M. Higher net loss reflects (Loss)/Gain on revaluation of derivative decrease from $8K (income) to $47K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$4.73 to -$3.75.

 CLRBのテクニカル分析


 CLRBのニュース

   Neuroblastoma Drug Market Demand, Growth Opportunities and Top Key Players Analysis- Cellectar Biosciences, INC, United Therapeutics Corporation, APEIRON Biologics AG, Baxter  2020/10/13 18:38:59 OpenPR
The large-scale Global Neuroblastoma Drug Market report provides details about market trends, future prospects, market restraints, leading market drivers, several market segments, key developments, key players in the market, and competitor strategies. This market study encompasses a market attractiveness analysis, wherein all
   The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic  2020/06/04 12:13:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 3) Cellectar Biosciences Inc (NASDAQ: CLRB ) (priced a $20-million common stock offering) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Genfit SA (NASDAQ: GNFT ) Stocks In Focus Kezar Reports Positive Early Stage Results For KZR-616 In Systemic Lupus Erythematosus Kezar Life Sciences, Inc. (NASDAQ: KZR ) announced updated results from the Phase 1b portion of the Phase 1b/2 MISSION study, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis, showing overall improvements across seven measures of disease activity.
   RGA, ARCE among premarket losers  2020/06/03 13:12:07 Seeking Alpha
Evofem Biosciences (NASDAQ:EVFM) -26% after pricing equity offering. Cellectar Biosciences (NASDAQ:CLRB) -20% after pricing $20M public offering. Reinsuran
   Stock Alert: Cellectar Shares Rally 34% In Premarket On FDA Fast Track Designation  2020/05/26 08:25:00 RTT News
Shares of Cellectar Biosciences Inc. (CLRB) are soaring over 34% in pre-market today, after the biopharmaceutical company announced that the U.S. FDA has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma or LPL/Waldenstrom's macroglobulinemia or WM in patients having received two prior treatment regimens or more.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic  2020/06/04 12:13:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 3) Cellectar Biosciences Inc (NASDAQ: CLRB ) (priced a $20-million common stock offering) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Genfit SA (NASDAQ: GNFT ) Stocks In Focus Kezar Reports Positive Early Stage Results For KZR-616 In Systemic Lupus Erythematosus Kezar Life Sciences, Inc. (NASDAQ: KZR ) announced updated results from the Phase 1b portion of the Phase 1b/2 MISSION study, which is evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus with and without nephritis, showing overall improvements across seven measures of disease activity.
   RGA, ARCE among premarket losers  2020/06/03 13:12:07 Seeking Alpha
Evofem Biosciences (NASDAQ:EVFM) -26% after pricing equity offering. Cellectar Biosciences (NASDAQ:CLRB) -20% after pricing $20M public offering. Reinsuran
   Stock Alert: Cellectar Shares Rally 34% In Premarket On FDA Fast Track Designation  2020/05/26 08:25:00 RTT News
Shares of Cellectar Biosciences Inc. (CLRB) are soaring over 34% in pre-market today, after the biopharmaceutical company announced that the U.S. FDA has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma or LPL/Waldenstrom's macroglobulinemia or WM in patients having received two prior treatment regimens or more.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.
   The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher  2019/11/13 12:10:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) Antares Pharma Inc (NASDAQ: ATRS ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bristol-Myers Squibb Co (NYSE: BMY ) Celgene Corporation (NASDAQ: CELG ) Crispr Therapeutics AG (NASDAQ: CRSP ) Diplomat Pharmacy Inc (NYSE: DPLO )( warned of going concern risk) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) DexCom, Inc. (NASDAQ: DXCM ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Galera Therapeutics Inc (NASDAQ: GRTX ) Insulet Corporation (NASDAQ: PODD ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) X T L Biopharmaceuticals Ltd (NASDAQ: XTLB ) XOMA Corp (NASDAQ: XOMA ) Zai Lab Ltd (NASDAQ: ZLAB ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov.
   Can We See Significant Institutional Ownership On The Cellectar Biosciences, Inc. (NASDAQ:CLRB) Share Register?  2019/08/20 16:37:22 Yahoo Finance
Every investor in Cellectar Biosciences, Inc. (NASDAQ:CLRB) should be aware of the most powerful shareholder groups…
   The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache  2019/06/05 11:30:44 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 4) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR Insulet Corporation (NASDAQ: PODD ) Mirati Therapeutics Inc (NASDAQ: MRTX )( reacted to analyst action) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Uniqure NV (NASDAQ: QURE ) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 4) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Cellectar Biosciences Inc (NASDAQ: CLRB ) Cidara Therapeutics Inc (NASDAQ: CDTX ) Collegium Pharmaceutical … Full story available on Benzinga.com
   Cellectar up 8% on continued advancement of CLR 131  2019/05/21 13:26:13 Seeking Alpha

 関連キーワード  (医薬品 米国株 セレクタ・バイオサイエンシ―ズ CLRB Cellectar Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)